vs
Side-by-side financial comparison of AbbVie (ABBV) and Option Care Health, Inc. (OPCH). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $1.4B, roughly 11.6× Option Care Health, Inc.). AbbVie runs the higher net margin — 10.9% vs 3.6%, a 7.3% gap on every dollar of revenue. On growth, Option Care Health, Inc. posted the faster year-over-year revenue change (12.2% vs 10.0%). AbbVie produced more free cash flow last quarter ($4.9B vs $130.2M). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 13.0%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
ABBV vs OPCH — Head-to-Head
Income Statement — Q4 2025 vs Q3 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $1.4B |
| Net Profit | $1.8B | $51.8M |
| Gross Margin | 72.6% | 19.0% |
| Operating Margin | 27.3% | 5.9% |
| Net Margin | 10.9% | 3.6% |
| Revenue YoY | 10.0% | 12.2% |
| Net Profit YoY | 8354.5% | -3.8% |
| EPS (diluted) | $1.02 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | — | ||
| Q3 25 | $15.8B | $1.4B | ||
| Q2 25 | $15.4B | $1.4B | ||
| Q1 25 | $13.3B | $1.3B | ||
| Q4 24 | $15.1B | $1.3B | ||
| Q3 24 | $14.5B | $1.3B | ||
| Q2 24 | $14.5B | $1.2B | ||
| Q1 24 | $12.3B | $1.1B |
| Q4 25 | $1.8B | — | ||
| Q3 25 | $186.0M | $51.8M | ||
| Q2 25 | $938.0M | $50.5M | ||
| Q1 25 | $1.3B | $46.7M | ||
| Q4 24 | $-22.0M | $60.1M | ||
| Q3 24 | $1.6B | $53.9M | ||
| Q2 24 | $1.4B | $53.0M | ||
| Q1 24 | $1.4B | $44.8M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 66.4% | 19.0% | ||
| Q2 25 | 71.8% | 19.0% | ||
| Q1 25 | 70.0% | 19.7% | ||
| Q4 24 | 70.9% | 21.3% | ||
| Q3 24 | 70.9% | 20.1% | ||
| Q2 24 | 70.9% | 20.3% | ||
| Q1 24 | 66.7% | 20.8% |
| Q4 25 | 27.3% | — | ||
| Q3 25 | 12.1% | 5.9% | ||
| Q2 25 | 31.7% | 5.8% | ||
| Q1 25 | 28.0% | 5.9% | ||
| Q4 24 | -9.9% | 6.9% | ||
| Q3 24 | 26.5% | 6.7% | ||
| Q2 24 | 27.6% | 6.6% | ||
| Q1 24 | 22.7% | 6.0% |
| Q4 25 | 10.9% | — | ||
| Q3 25 | 1.2% | 3.6% | ||
| Q2 25 | 6.1% | 3.6% | ||
| Q1 25 | 9.6% | 3.5% | ||
| Q4 24 | -0.1% | 4.8% | ||
| Q3 24 | 10.8% | 4.2% | ||
| Q2 24 | 9.5% | 4.3% | ||
| Q1 24 | 11.1% | 3.9% |
| Q4 25 | $1.02 | — | ||
| Q3 25 | $0.10 | $0.32 | ||
| Q2 25 | $0.52 | $0.31 | ||
| Q1 25 | $0.72 | $0.28 | ||
| Q4 24 | $-0.03 | $0.36 | ||
| Q3 24 | $0.88 | $0.31 | ||
| Q2 24 | $0.77 | $0.30 | ||
| Q1 24 | $0.77 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $309.8M |
| Total DebtLower is stronger | $58.9B | $1.2B |
| Stockholders' EquityBook value | $-3.3B | $1.4B |
| Total Assets | $134.0B | $3.5B |
| Debt / EquityLower = less leverage | — | 0.86× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.7B | $309.8M | ||
| Q2 25 | $6.5B | $198.8M | ||
| Q1 25 | $5.2B | $171.4M | ||
| Q4 24 | $5.6B | $412.6M | ||
| Q3 24 | $7.3B | $483.0M | ||
| Q2 24 | $13.2B | $376.9M | ||
| Q1 24 | $18.1B | $219.5M |
| Q4 25 | $58.9B | — | ||
| Q3 25 | $63.0B | $1.2B | ||
| Q2 25 | $63.0B | $1.1B | ||
| Q1 25 | $64.5B | $1.1B | ||
| Q4 24 | $60.3B | $1.1B | ||
| Q3 24 | $58.5B | $1.1B | ||
| Q2 24 | $58.0B | $1.1B | ||
| Q1 24 | $63.8B | $1.1B |
| Q4 25 | $-3.3B | — | ||
| Q3 25 | $-2.6B | $1.4B | ||
| Q2 25 | $-183.0M | $1.4B | ||
| Q1 25 | $1.4B | $1.4B | ||
| Q4 24 | $3.3B | $1.4B | ||
| Q3 24 | $6.0B | $1.4B | ||
| Q2 24 | $6.8B | $1.4B | ||
| Q1 24 | $8.0B | $1.4B |
| Q4 25 | $134.0B | — | ||
| Q3 25 | $133.9B | $3.5B | ||
| Q2 25 | $137.2B | $3.4B | ||
| Q1 25 | $136.2B | $3.3B | ||
| Q4 24 | $135.2B | $3.4B | ||
| Q3 24 | $143.4B | $3.4B | ||
| Q2 24 | $141.9B | $3.3B | ||
| Q1 24 | $148.9B | $3.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.86× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | 45.44× | 0.82× | ||
| Q4 24 | 18.15× | 0.79× | ||
| Q3 24 | 9.70× | 0.78× | ||
| Q2 24 | 8.56× | 0.79× | ||
| Q1 24 | 7.97× | 0.74× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | $139.4M |
| Free Cash FlowOCF − Capex | $4.9B | $130.2M |
| FCF MarginFCF / Revenue | 29.4% | 9.1% |
| Capex IntensityCapex / Revenue | 2.0% | 0.6% |
| Cash ConversionOCF / Net Profit | 2.87× | 2.69× |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | $220.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | $139.4M | ||
| Q2 25 | $5.2B | $90.3M | ||
| Q1 25 | $1.6B | $-7.2M | ||
| Q4 24 | $7.0B | $36.1M | ||
| Q3 24 | $5.4B | $160.4M | ||
| Q2 24 | $2.3B | $195.7M | ||
| Q1 24 | $4.0B | $-68.8M |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | $130.2M | ||
| Q2 25 | $4.9B | $81.2M | ||
| Q1 25 | $1.4B | $-16.6M | ||
| Q4 24 | $6.8B | $25.8M | ||
| Q3 24 | $5.2B | $150.7M | ||
| Q2 24 | $2.0B | $185.9M | ||
| Q1 24 | $3.8B | $-74.6M |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | 9.1% | ||
| Q2 25 | 31.7% | 5.7% | ||
| Q1 25 | 10.5% | -1.2% | ||
| Q4 24 | 44.7% | 2.0% | ||
| Q3 24 | 35.9% | 11.8% | ||
| Q2 24 | 14.0% | 15.1% | ||
| Q1 24 | 31.3% | -6.5% |
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | 0.6% | ||
| Q2 25 | 1.7% | 0.6% | ||
| Q1 25 | 1.8% | 0.7% | ||
| Q4 24 | 1.9% | 0.8% | ||
| Q3 24 | 1.7% | 0.8% | ||
| Q2 24 | 1.7% | 0.8% | ||
| Q1 24 | 1.6% | 0.5% |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | 2.69× | ||
| Q2 25 | 5.49× | 1.79× | ||
| Q1 25 | 1.27× | -0.15× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | 3.49× | 2.98× | ||
| Q2 24 | 1.66× | 3.69× | ||
| Q1 24 | 2.95× | -1.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
OPCH
| Commercial Customer | $1.3B | 87% |
| Government Customer | $172.8M | 12% |
| Patient Customer | $10.1M | 1% |
| Corporate Joint Venture | $1.9M | 0% |
